Company Overview and News

 
Mantle Mining Corporation shares rise on revealing gold potential

2017-05-15 proactiveinvestors.com.au
Mantle Mining Corporation (ASX:MNM) has completed a structural reinterpretation and historical review of the high-grade Kenny’s zone at the Morning Star gold mine in Eastern Victoria.

 
Mantle Mining Corporation's shares in pre-open

2017-03-27 proactiveinvestors.com.au
Mantle Mining Corporation (ASX:MNM) has been granted a trading halt by the ASX, pending details of a possible refinancing.

 
Mantle Mining Corporation hints at high-grade gold in Morning Star

2017-02-13 proactiveinvestors.com.au
Mantle Mining Corporation (ASX:MNM) has revealed an important breakthrough in its strategy to develop the high-grade Morning Star and Rose of Denmark gold mines in eastern Victoria.

 
Mantle Mining Corporation Ltd to conduct portfolio review

2016-08-18 proactiveinvestors.com.au
Mantle Mining Corporation Ltd (ASX:MNM) has been granted a trading halt by the ASX, pending the outcome of a review of its portfolio of gold and coal assets. The halt will remain in place until the opening of trade on Monday 22nd August 2016, or earlier if an announcement is made to the market.

 
Mantle Mining Corporation Ltd raising funds as gold concentrate nears

2016-07-22 proactiveinvestors.com.au
Mantle Mining Corporation Ltd (ASX:MNM) is progressing towards the first gold concentrate production from the Norton Gold Mine. Sorter trials have been completed and gravity plant trials are underway using bulk sample material. Mantle Mining has this morning been granted a trading halt, pending details of a capital raising. The halt will remain in place until the opening of trade on Tuesday 26th July 2016, or earlier if an announcement is made to the market.

 
Mantle Mining Corporation Ltd eyes restart at Morning Star gold mine

2016-07-07 proactiveinvestors.com.au
Mantle Mining Corporation Ltd (ASX:MNM) is edging closer to a re-start of mining at its newly acquired Morning Star gold mine in the gold fields of Victoria. With a scond payment of $1 million to the vendor of Morning Star gold mine, it has two more payments to complete the acquisition price for the mine in eastern Victoria. In the late 1950’s Morning Star was one of Australia’s largest gold mines having reportedly produced in excess of 800,000 ounces of gold at an average grade of 26.

 
Mantle Mining Corporation Ltd has production plans for Morning Star Gold Mine

2016-06-15 proactiveinvestors.com.au
Mantle Mining Corporation Ltd's (ASX:MNM) principal activities are to acquire exploration tenements and locate economically developable deposits of coal and gold.

 
Completion of Capital Raising

2016-05-09 asx.com.au

 
Trading Halt

2016-05-04 asx.com.au

 
Quarterly Cashflow Report

2016-04-29 asx.com.au

 
Quarterly Activities Report

2016-04-29 asx.com.au

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...